Description: |
The life expectancies of people with advanced melanoma may be doubled, thanks to a new drug that harnesses the power of patients' immune systems to fight their cancer. Nivolumab (Opdivo), slowed cancer progression in melanoma patients by more than double, compared with an earlier immunotherapy drug called ipilimumab (Yervoy). What's more, the delay in cancer progression nearly quadrupled when the two drugs were combined, compared with taking ipilimumab alone. [Source: WebMD]
|
|